Stone Size Stratified Effect of Adjuvant Silodosin on Stone Clearance After ESWL for Renal Stones

Prospective Randomized Controlled Trial to evaluate effectiveness of adjuvant Silodosin for Improving the Stone-Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260212007

Enrollment

100

Registered

2026-02-12

Start date

2023-04-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal stones Silodosin Renal stones Extracorporeal shock wave lithotripsy Stone clearance

Interventions

Patients received oral silodosin 4 mg twice daily for 30 days following extracorporeal shock wave lithotripsy (ESWL), in addition to standard postoperative care including pain control and intravenous

Experimental Drug,Active Comparator Other

Silodosin,Standard care without silodosin

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Adult patients aged 18 to 70 years with renal stones undergoing extracorporeal shock wave lithotripsy and stone size less than 20 mm.

Exclusion criteria

Exclusion criteria: Active urinary tract infection, baseline hypotension, coagulopathy, history of hypersensitivity to silodosin, significant hepatic impairment, or history of previous pyeloureteral surgery,Pregnant or breastfeeding women.

Design outcomes

Primary

Measure	Time frame
Stone-free rate 3 months Plain abdominal radiography (KUB) and assessment of stone-related symptoms	—

Secondary

Measure	Time frame
Post-ESWL complications 1 month Patient interview and clinical record review	—

Countries

Thailand

Contacts

Public ContactPHANPON LEELAHAWONG

Rayong Hospital

phanpon@hotmail.com0815365954

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026